Analysis of the effect of HDAC inhibitors on the formation of the HIV reservoir.
Lijun LingManse KimAndrew SoperMartina KovarovaRae Ann SpagnuoloNurjahan BegumJennifer KirchherrNancie M ArchinDiana BattagliaDave ClevelandAngela WahlDavid M MargolisEdward P BrowneJ Victor Garcia-MartinezPublished in: mBio (2024)
The HIV reservoir is more dynamic than previously thought with around 70% of the latent reservoir originating from viruses circulating within 1 year of the initiation of antiretroviral therapy (ART). In an ex vivo model system of HIV latency, it was reported that early exposure to class I histone deacetylase (HDAC) inhibitors might prevent these more recently infected cells from entering a state of stable viral latency. This finding raises the possibility that co-administration of HDAC inhibitors at the time of ART initiation may prevent the establishment of much of the HIV reservoir. Here, we tested the effects of the HDAC inhibitors suberoylanilide hydroxamic acid (SAHA) and panobinostat co-administered at the time of ART initiation on the formation of the viral reservoir in HIV-infected humanized mice. As previously shown, SAHA and panobinostat were well tolerated in humanized mice. Unexpectedly, co-administration of SAHA resulted in an increase in the frequency of CD4 + cells carrying HIV DNA but did not alter the frequency of cell-associated HIV RNA in HIV-infected, ART-treated humanized mice. Co-administration of panobinostat did not alter levels of cell-associated HIV DNA or RNA. Our in vivo findings indicate that co-administration of HDAC inhibitors initiated at the same time of ART treatment does not prevent recently infected cells from entering latency.IMPORTANCECurrent antiretroviral therapy (ART) does not eradicate cells harboring replication-competent HIV reservoir. Withdrawal of ART inevitably results in a rapid viremia rebound. The HIV reservoir is more dynamic than previously thought. Early exposure to class I histone deacetylase (HDAC) inhibitors inhibit these more recently infected cells from entering a state of stable viral latency in an ex vivo model of latency, raising the possibility that co-administration of HDAC inhibitors at the time of ART initiation may reduce much of the HIV reservoir. Here, we tested the effects of the HDAC inhibitors suberoylanilide hydroxamic acid or panobinostat during ART initiation on the formation of the viral reservoir in HIV-infected humanized mice. Our in vivo study indicates that in contrast to in vitro observations, the co-administration of HDAC inhibitors at the same time of ART initiation does not prevent recently infected cells from entering latency.
Keyphrases
- antiretroviral therapy
- hiv infected
- histone deacetylase
- hiv positive
- human immunodeficiency virus
- hiv infected patients
- hiv aids
- stem cells
- hepatitis c virus
- metabolic syndrome
- induced apoptosis
- computed tomography
- high fat diet induced
- skeletal muscle
- oxidative stress
- cell proliferation
- hiv testing
- bone marrow
- newly diagnosed
- type diabetes
- contrast enhanced
- insulin resistance
- magnetic resonance
- water quality
- combination therapy
- south africa